What risks and matters need to be paid attention to while using Omalizumab?

Omalizumab (Omalizumab), as a biological agent targeting IgE, has been widely used in the treatment of moderate to severe allergic asthma and chronic spontaneous urticaria. Although this drug has excellent efficacy and high safety, there are still some risks and precautions that deserve the attention of patients and doctors during its use. Standardizing medication, closely observing adverse reactions, and actively managing related risks are the keys to ensuring treatment effectiveness and patient safety.

1. Be wary of serious adverse reactions such as anaphylactic shock

Although omalizumab is a humanized antibody and has low allergenicity, a very small number of patients may experience severe allergic reactions such as anaphylactic shock (anaphylaxis) after taking the drug. This type of reaction may occur within minutes to hours after injection, manifesting as dyspnea, laryngeal edema, hypotension, disturbance of consciousness, etc., and may be life-threatening in severe cases. According to foreign drug regulatory data, its incidence rate is approximately 0.1%.

To reduce the risk, it is recommended that patients receive treatment in the hospital during the first injection or initial stage of medication and observe at least 30–60 minutes after the injection. If a severe allergic reaction has occurred, epinephrine should be used for subsequent injections. Patients should be familiar with the early manifestations of allergic reactions, and family members should also receive necessary first aid instruction to respond promptly.

2. Injection site reactions and skin symptom management

Omalizumab is administered by subcutaneous injection. Some patients may experience local redness, swelling, induration, itching or pain after injection. These reactions are mostly mild to moderate and usually resolve within 1–3 days without affecting continued medication. To reduce discomfort, apply cold compresses appropriately after the injection and avoid vigorous rubbing of the area.

If the reaction at the injection site lasts for more than 48 hours or worsens gradually, you need to seek medical examination to rule out infection or other allergic diseases. In addition, a very few patients have reported skin abnormalities such as rash, eczema-like changes, and pigmentation during use. It is necessary to decide whether to continue taking the medication or adjust the treatment plan based on the specific symptoms.

3. Impact on the immune system and risk of infection

Omalizumab mainly works by neutralizingIgE and may theoretically have a slight impact on some immune mechanisms. Some patients may experience mild upper respiratory tract infection, nasopharyngitis, cough, headache or throat discomfort during use, but most of them are self-limiting and the symptoms are mild.

It should be emphasized that omalizumab does not broadly suppress the immune system, and the risk of infection in long-term users is not significantly increased. However, during medication, it is still recommended to maintain good hygiene habits and avoid frequent contact with sources of respiratory infections. If you have high fever, persistent cough, chest tightness and other suspected infection symptoms, you should seek medical treatment in time to check for potential pulmonary or systemic infection.

4. Combined medication for chronic diseases and medication for special populations

Some patients with asthma or urticaria are complicated by other chronic diseases, such as hypertension, diabetes, heart disease, etc., so they need to pay special attention to drug interactions when using omalizumab. The drug has not been found to conflict with conventional antihypertensive, antidiabetic, or antidepressant medications, but patients are advised to inform their physician of a list of all medications they are taking for evaluation.

Sufficient human data are lacking for omalizumab in pregnant and lactating women. Although animal tests have not shown obvious teratogenic effects, it should still be used with caution in pregnant women weighing the pros and cons. It is not clear whether it can be secreted into breast milk during lactation. It is recommended to use it with caution or alternative treatment under the guidance of a doctor.

5. Medication cycle and efficacy evaluation

Omalizumab is not a one-time medication, and most treatments need to be continued to achieve the best results. Asthma patients usually need injections every 2–4 weeks, and the course of treatment lasts at least 3–6 months; patients with urticaria are usually injected once every 4 weeks, and the course of treatment depends on the control of symptoms. Periodic review should be performed during use, such as pulmonary function testing, IgE level monitoring and symptom assessment, to decide whether to continue, reduce or discontinue the drug.

The efficacy varies greatly among individuals. Some patients can improve significantly within a few weeks, while others have a slower onset of effect and need to be observed for more than 1–3 months. If there is still no significant improvement after continuous use for 3 months, the treatment strategy needs to be adjusted under the evaluation of a doctor. It should be avoided to stop the medication or change the medication regimen at will because it does not show effect in the early stage, so as not to affect the disease control.

Omalizumab is a relatively safe biological agent, but there are still some potential risks that need to be paid attention to during use, including injection reactions, allergic risks, infection tendencies, and individual medication differences. It is recommended that patients take medication strictly in accordance with medical instructions, receive initial injections in the hospital and stay under observation, follow up regularly on efficacy and safety, and make individualized treatment adjustments when necessary. Through scientific and standardized use of this drug, its therapeutic advantages can be maximized while reducing the possibility of side effects, helping patients better control the disease and improve their quality of life.

Reference materials:https://www.drugs.com/